Sarepta Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Private, Public
- Established
- 1980-01-01
- Employees
- 1.3K
- Market Cap
- $13.4B
- Website
- http://www.sarepta.com
- Introduction
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.
A Study of SRP-9005 in Limb Girdle Muscular Dystrophy Type 2C/R5 Pediatric and Adult Participants
- Conditions
- Muscular Dystrophies, Limb-Girdle
- Interventions
- Drug: Corticosteroid
- First Posted Date
- 2025-05-01
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- Sarepta Therapeutics, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT06952686
Study to Evaluate the Safety, Tolerability, and Efficacy of SRP-9004 Administered by Systemic Infusion in Limb Girdle Muscular Dystrophy Type 2D/R3 Participants in the United States
- Conditions
- Limb Girdle Muscular DystrophyLimb Girdle Muscular Dystrophy Type 2D/R3
- Interventions
- First Posted Date
- 2024-12-24
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Sarepta Therapeutics, Inc.
- Target Recruit Count
- 4
- Registration Number
- NCT06747273
- Locations
- 🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States
🇺🇸Children's Hospital of the King's Daughters, Norfolk, Virginia, United States
A Long-term Observational Study Evaluating Eteplirsen, Golodirsen, or Casimersen in Routine Clinical Practice
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- First Posted Date
- 2024-09-23
- Last Posted Date
- 2024-09-23
- Lead Sponsor
- Sarepta Therapeutics, Inc.
- Target Recruit Count
- 300
- Registration Number
- NCT06606340
- Locations
- 🇺🇸
Arkansas Children's Hospital Research Institute, Little Rock, Arkansas, United States
🇺🇸Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸University of California Davis Medical Center, Sacramento, California, United States
A Gene Transfer Therapy to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Therapeutic Plasma Exchange (Plasmapheresis) in Participants With Duchenne Muscular Dystrophy (DMD) and Pre-existing Antibodies to AAVrh74
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- Genetic: delandistrogene moxeparvovecProcedure: Plasmapheresis
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-03-03
- Lead Sponsor
- Sarepta Therapeutics, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT06597656
- Locations
- 🇺🇸
Washington University School of Medicine in St. Louis, Saint Louis, Missouri, United States
🇺🇸Nationwide Children's Hospital, Columbus, Ohio, United States
An Observational Study Comparing Delandistrogene Moxeparvovec With Standard of Care in Participants With Duchenne Muscular Dystrophy
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- Genetic: Delandistrogene MoxeparvovecDrug: Standard of Care
- First Posted Date
- 2024-02-21
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Sarepta Therapeutics, Inc.
- Target Recruit Count
- 500
- Registration Number
- NCT06270719
- Locations
- 🇺🇸
Ann and Robert H Lurie Childrens Hospital of Chicago, Chicago, Illinois, United States
🇺🇸The Medical College of Wisconsin, Milwaukee, Wisconsin, United States
🇺🇸Arkansas Children's Hospital, Little Rock, Arkansas, United States
A Trial to Learn More About an Experimental Gene Therapy Called Bidridistrogene Xeboparvovec (SRP-9003) as a Possible Treatment for Limb Girdle Muscular Dystrophy 2E/R4
- Conditions
- Limb-girdle Muscular Dystrophy
- Interventions
- First Posted Date
- 2024-02-07
- Last Posted Date
- 2025-04-06
- Lead Sponsor
- Sarepta Therapeutics, Inc.
- Target Recruit Count
- 17
- Registration Number
- NCT06246513
- Locations
- 🇺🇸
University of California, San Diego-Altman Clinical and Translational Research Institute, La Jolla, California, United States
🇺🇸Nationwide Childrens Hospital, Columbus, Ohio, United States
🇺🇸The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Imlifidase Infusion in Participants With Duchenne Muscular Dystrophy (DMD) Determined to Have Pre-existing Antibodies to Recombinant Adeno-Associated Virus Serotype (rAAVrh74)
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- Genetic: delandistrogene moxeparvovec
- First Posted Date
- 2024-02-05
- Last Posted Date
- 2025-03-03
- Lead Sponsor
- Sarepta Therapeutics, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT06241950
- Locations
- 🇪🇸
Hospital Sant Joan de Déu, Barcelona, Spain
A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical Study
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- Genetic: delandistrogene moxeparvovec
- First Posted Date
- 2023-08-01
- Last Posted Date
- 2025-01-17
- Lead Sponsor
- Sarepta Therapeutics, Inc.
- Target Recruit Count
- 400
- Registration Number
- NCT05967351
- Locations
- 🇬🇧
Oxford University Hospitals NHS Foundation Trust, Oxford, Oxfordshire, United Kingdom
🇺🇸Arkansas Children's Hospital, Little Rock, Arkansas, United States
🇺🇸UCLA Medical Center, Los Angeles, California, United States
A Gene Transfer Study to Evaluate the Safety, Tolerability and Efficacy of SRP-6004 in Ambulatory Participants With Limb Girdle Muscular Dystrophy, Type 2B/R2 (LGMD2B/R2, Dysferlin [DYSF] Related)
- Conditions
- Limb Girdle Muscular Dystrophy
- Interventions
- Genetic: SRP-6004
- First Posted Date
- 2023-06-15
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Sarepta Therapeutics, Inc.
- Target Recruit Count
- 2
- Registration Number
- NCT05906251
- Locations
- 🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States
A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- Genetic: delandistrogene moxeparvovecGenetic: placebo
- First Posted Date
- 2023-05-31
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- Sarepta Therapeutics, Inc.
- Target Recruit Count
- 148
- Registration Number
- NCT05881408
- Locations
- 🇰🇷
Gangnam Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of
🇺🇸Arkansas Children's Hospital, Little Rock, Arkansas, United States
🇺🇸Lucile Packard Children's Hospital Stanford, Palo Alto, California, United States